{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2008"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Cancer"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2052708"],"location":["United States"],"study_start_month":["3"],"keyword":["Erlotinib Hydrochloride","Irinotecan","Oxaliplatin","Colorectal","Leucovorin","Metastatic","Colon","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)","description":"The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer. The investigator will also be studying the side effects (good and bad) of alternating chemotherapy with erlotinib on metastatic colorectal cancer.","dates":{"creation":"2008-03-15"},"accession":"2052708","cross_references":{"ClinicalTrials___gov":["NCT00642746"]}}